Cargando…

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR ‐mutated NSCLC

BACKGROUND: The relationship between epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance, including osimertinib, and programmed cell death‐ligand 1 (PD‐L1) expression status in EGFR‐mutated non‐small cell lung carcinoma (NSCLC) remains unclear. PATIENTS AND METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamakawa, Yusuke, Agemi, Yoko, Shiba, Aya, Ikeda, Toshiki, Higashi, Yuko, Aga, Masaharu, Miyazaki, Kazuhito, Taniguchi, Yuri, Misumi, Yuki, Nakamura, Yukiko, Shimokawa, Tsuneo, Saigusa, Yusuke, Kobayashi, Nobuaki, Okamoto, Hiroaki, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523952/ https://www.ncbi.nlm.nih.gov/pubmed/37548381 http://dx.doi.org/10.1002/cam4.6405

Ejemplares similares

Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study
por: Miyazaki, Kazuhito, et al.
Publicado: (2022)

Legionella pneumophila pneumonia with rapid clinical course in a lung cancer patient
por: Aga, Masaharu, et al.
Publicado: (2021)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

A case of pulmonary tumor thrombotic microangiopathy following lymphedema on the lower extremities
por: Shiraiwa, Yuri, et al.
Publicado: (2022)

Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study
por: Miyazaki, Kazuhito, et al.
Publicado: (2022)

Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap
por: Miyazaki, Kazuhito, et al.
Publicado: (2021)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
por: Aiko, Naoto, et al.
Publicado: (2018)

Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study
por: Agemi, Yoko, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors—retrospective study
por: Higaki, Hajime, et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

Rare ashy dermatosis‐like hyperpigmentation associated with osimertinib
por: Funai, Kazuhito
Publicado: (2022)

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
por: Ji, Jingran, et al.
Publicado: (2023)

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC
por: Han, Rui, et al.
Publicado: (2023)

PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
por: Racherla, Kavya Sri, et al.
Publicado: (2023)

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
por: Morimoto, Kenji, et al.
Publicado: (2022)

Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease
por: Yagyu, Hiroyuki, et al.
Publicado: (2020)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
por: Crowley, Fionnuala, et al.
Publicado: (2021)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
por: Piper-Vallillo, A.J., et al.
Publicado: (2022)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
por: Zhai, Xiaoyang, et al.
Publicado: (2021)

Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease
por: Inoue, Rei, et al.
Publicado: (2021)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report
por: Gerber, David E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f94vs7rvlcgfsl0edk19t059nv